Lorlatinib

Drug Profile

Lorlatinib

Alternative Names: PF-06463922; PF-6463922

Latest Information Update: 25 May 2017

Price : $50

At a glance

  • Originator Pfizer
  • Developer Pfizer; The Childrens Hospital of Philadelphia; Yale University
  • Class Antineoplastics; Aza compounds; Benzoxazines; Pyrazoles; Pyrazolones; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; ROS1-protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Preclinical Neuroblastoma

Most Recent Events

  • 25 May 2017 Pfizer completes a phase I drug-drug interaction trial in Healthy volunteers in Belgium (NCT02838264)
  • 16 May 2017 Chemical structure information added
  • 02 May 2017 Lorlatinib is available for expanded access (NCT03127618)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top